Fulcrum Therapeutics (NASDAQ:FULC) Stock Rating Reaffirmed by Cantor Fitzgerald

Fulcrum Therapeutics (NASDAQ:FULC)‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, Benzinga reports. They currently have a $23.00 price objective on the stock. Cantor Fitzgerald’s price target points to a potential upside of 194.87% from the company’s previous close.

Several other analysts also recently weighed in on FULC. Royal Bank of Canada began coverage on shares of Fulcrum Therapeutics in a report on Wednesday, March 13th. They issued an “outperform” rating and a $14.00 target price for the company. Oppenheimer reduced their price objective on shares of Fulcrum Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, May 14th. The Goldman Sachs Group raised Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $6.00 to $15.00 in a report on Monday, May 13th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Fulcrum Therapeutics in a report on Tuesday, May 14th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Fulcrum Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $15.57.

Fulcrum Therapeutics Trading Up 10.0 %

Shares of NASDAQ:FULC opened at $7.80 on Wednesday. Fulcrum Therapeutics has a 12-month low of $3.14 and a 12-month high of $13.70. The business has a 50 day moving average of $7.26 and a two-hundred day moving average of $8.06. The company has a market capitalization of $484.80 million, a PE ratio of -4.88 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC) last announced its earnings results on Monday, May 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.01. Fulcrum Therapeutics had a negative net margin of 3,470.05% and a negative return on equity of 40.60%. Equities research analysts predict that Fulcrum Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in FULC. Vanguard Group Inc. increased its holdings in Fulcrum Therapeutics by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock valued at $23,965,000 after acquiring an additional 18,681 shares in the last quarter. Vestal Point Capital LP purchased a new position in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $6,919,000. ADAR1 Capital Management LLC acquired a new position in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $4,302,000. Jane Street Group LLC raised its position in shares of Fulcrum Therapeutics by 54.3% during the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock worth $5,051,000 after purchasing an additional 188,212 shares during the last quarter. Finally, StemPoint Capital LP lifted its stake in Fulcrum Therapeutics by 8.1% in the 1st quarter. StemPoint Capital LP now owns 407,108 shares of the company’s stock valued at $3,843,000 after buying an additional 30,535 shares in the last quarter. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.